DarioHealth (DRIO) to Post Earnings on Tuesday

DarioHealth (NASDAQ:DRIO) is expected to be issuing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect DarioHealth to post earnings of ($0.74) per share and revenue of $5.92 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

DarioHealth Price Performance

DRIO traded up $0.07 during midday trading on Tuesday, reaching $7.17. 52,161 shares of the company’s stock were exchanged, compared to its average volume of 13,971. The business’s 50-day moving average price is $7.12 and its 200 day moving average price is $8.50. The stock has a market capitalization of $52.68 million, a PE ratio of -0.81 and a beta of 1.09. DarioHealth has a 1-year low of $5.84 and a 1-year high of $17.74. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.07 and a quick ratio of 2.62.

Insider Activity at DarioHealth

In other news, Director Dennis Matheis acquired 14,430 shares of the business’s stock in a transaction dated Thursday, July 23rd. The stock was acquired at an average price of $6.93 per share, with a total value of $99,999.90. Following the completion of the transaction, the director directly owned 43,026 shares in the company, valued at approximately $298,170.18. This represents a 50.46% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.50% of the stock is currently owned by company insiders.

Institutional Trading of DarioHealth

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd grew its holdings in DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after buying an additional 43,513 shares during the period. Geode Capital Management LLC lifted its holdings in shares of DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after acquiring an additional 31,063 shares during the period. Finally, Kestra Advisory Services LLC purchased a new position in shares of DarioHealth during the 4th quarter worth about $35,000. 33.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DRIO has been the topic of a number of recent research reports. TD Cowen reaffirmed a “hold” rating and issued a $11.00 target price on shares of DarioHealth in a research note on Wednesday, May 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research report on Friday, July 10th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $10.00 price target on shares of DarioHealth in a report on Thursday, May 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.50.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.